IP Library Granted Patent US 12,005,052
Granted Patent B2
US 12,005,052 · App. 18/353,869 · Granted Jun 11, 2024

Topical roflumilast formulation having improved delivery and plasma half-life

Inventor: David W. Osborne (Fort Collins, CO)
Assignee: ARCUTIS BIOTHERAPEUTICS, INC.
A61K31/44A61K9/0014A61K45/06A61K47/06A61K47/10A61K47/14A61K47/24A61P17/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,005,052
App. No.
18/353,869
Granted
Jun 11, 2024
Kind
B2
Abstract

The present invention is directed to methods for improving the therapeutic outcome of treatment with roflumilast. The therapeutic outcome is improved by consistent delivery and/or a longer plasma half-life of a topically administered roflumilast composition. The roflumilast composition preferably includes dicetyl phosphate, ceteth-10 phosphate, diethylene glycol I monoethyl ether, and/or hexylene glycol.

Claims (19)

1. A pharmaceutical composition for topical administration comprising:

(i) roflumilast, wherein the roflumilast is in an amount of 0.05-1.0% w/w;

(ii) water;

(iii) diethylene glycol monoethyl ether; and

(iv) an emulsifier blend comprising cetostearyl alcohol, dicetyl phosphate and ceteth-10 phosphate;

wherein the plasma half-life of the roflumilast is between 3 and 5 days after topical administration of the composition.

2. The composition according to claim 1 , wherein said composition comprises about 10% w/w of said emulsifier blend.

3. The composition according to claim 1 , wherein said composition comprises about 25% w/w diethylene glycol monoethyl ether.

4. The composition according to claim 1 , wherein said composition comprises w/w roflumilast.

5. The composition according to claim 4 , wherein said composition comprises about 10% w/w of said emulsifier blend.

6. The composition according to claim 4 , wherein said composition comprises about 25% diethylene glycol monoethyl ether.

7. A pharmaceutical composition for topical administration comprising:

(i) roflumilast in an amount of 0.05-1.0% w/w;

(ii) water qs ad 100% w/w;

(iii) diethylene glycol monoethyl ether in an amount of 10-30% w/w; and

(iv) an emulsifier blend comprising cetostearyl alcohol, dicetyl phosphate and ceteth-10 phosphate in an amount of 1.0-25% w/w;

wherein the composition is a foam or cream.

8. The composition according to claim 7 , wherein said composition is a foam, and wherein said composition comprises 25% w/w diethylene glycol monoethyl ether, 2% w/w emulsifier blend, white petrolatum, and isopropyl palmitate.

9. The composition according to claim 7 , wherein said composition is a cream, and wherein said composition comprises 25% w/w diethylene glycol monoethyl ether, 10% w/w emulsifier blend, 10.0% w/w white petrolatum, and 5.0% w/w isopropyl palmitate.

Assignments (3)
SECURITY INTEREST Recorded Aug 9, 2024
From: ARCUTIS BIOTHERAPEUTICS, INC.
To: SLR INVESTMENT CORP.
Reel/Frame 068236/0418 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2024
From: OSBORNE, DAVID W.
To: ARCUTIS, INC.
Reel/Frame 066821/0437 →
CHANGE OF NAME Recorded Mar 19, 2024
From: ARCUTIS, INC.
To: ARCUTIS BIOTHERAPEUTICS, INC.
Reel/Frame 066821/0809 →
Continuity (8)
Continuation 18176601 · Mar 1, 2023
Continuation 17402051 · Aug 13, 2021
Continuation 16778845 · Jan 31, 2020
Continuation In Part 16136804 · Sep 20, 2018
Continuation 15848505 · Dec 20, 2017
Continuation 15676356 · Aug 14, 2017
Division 15616409 · Jun 7, 2017
Related Publication 20230364066A1 · Nov 16, 2023
Cited By (1)
US 12,310,956